Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Jefferson Research
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Allergan Inc raises FY 2014 outlook; gives FY 2015, 2016 EPS outlook above analysts' estimates; gives Q3 2014 outlook in line with analysts' estimates; gives charge outlook


Monday, 21 Jul 2014 08:00am EDT 

Allergan Inc:Sees FY 2014 EPS between $5.74 and $5.80.Sees FY 2015 EPS between $8.20 and $8.40.Sees FY 2016 EPS at about $10.00.Expects to incur total non-recurring pre-tax charges of between $375 and $425 million in connection with the restructuring and other costs.Sees FY 2014 total product net sales between $6.90 and $7.05 bln excluding any future anticipated revenue from the transition services agreements related to the sale of the obesity intervention business.Sees Q3 2014 total product net sales between $1.675 and $1.750 bln, excluding any future anticipated revenue from the transition services agreements related to the sale of the obesity intervention business.Sees Q3 2014 non-GAAP diluted earnings per share between $1.44 and $1.47.FY 2014 EPS $5.70 and revenue of $6.98 bln - Thomson Reuters I/B/E/S.FY 2015 EPS $6.85 - Thomson Reuters I/B/E/S.FY 2016 EPS $8.14 - Thomson Reuters I/B/E/S.Q3 2014 EPS $1.45 and revenue of $1.72 bln - Thomson Reuters I/B/E/S. 

Company Quote

212.63
0.45 +0.21%
19 Dec 2014